Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides
Molecular Pharmaceutics · 05.10.2026 · 23 (10) · 4872-4883
DOI: 10.1021/acs.molpharmaceut.6c00409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.09.2026. Verfasst von Christian Weinmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Grenzacherstrasse 124, Basel4070, Switzerland. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Liquid Chromatography-Mass Spectrometry, Peptides, Cyclic, Peptides. Die Arbeit nennt 55 Literaturangaben. Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, Roche.
Abstract (Originalsprache)
The landscape of drug discovery has expanded beyond the traditional chemical space into the domain of large, flexible molecules, including beyond rule-of-five (bRo5) macrocyclic peptides (MCPs). Molecular chameleonicity, the capacity to dynamically adapt the conformation to the environment, balancing aqueous solubility and membrane permeability, has the potential to improve the oral bioavailability of these compounds. However, we lack experimental methods that quantify chameleonicity in a high-throughput manner. To address this need, we introduce DynlogP, a novel high-throughput, fully automated assay based on reverse-phase LC−MS that can quantify chameleonicity with minimal compound input. DynlogP measures calibrated lipophilicity under conditions promoting either solvent hydrogen bonding (log P70) or intramolecular hydrogen bonding (log P95), providing a quantitative measure of chameleonicity (Δlog P95−70) that is validated with NMR and molecular dynamics simulations. We profiled hundreds of molecules with DynlogP and demonstrate that chameleonicity is a common feature of MCPs. Machine learning models trained with DynlogP data allow for the prospective prediction of chameleonicity. Adoption and further refinement of DynlogP have the potential to empower compound prioritization and the design of orally bioavailable MCP-based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Grenzacherstrasse 124, Basel4070, Switzerland.
- Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich8093, Switzerland.
ORCID-Profile: Christian Weinmann, Franz Waibl, Silvan Käser, Fabio Casagrande, Jitao David Zhang, Fabian Dey, Björn Wagner, Britta Schulze, Carsten Kroll, Janneke Keemink
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- Roche
Zitieren
APA
Weinmann, C., Waibl, F., Käser, S., Casagrande, F., Zhang, J. D., Dey, F., Wagner, B., Schulze, B., Kroll, C., & Keemink, J. (2026). Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides. Molecular Pharmaceutics, 23(10), 4872-4883. https://doi.org/10.1021/acs.molpharmaceut.6c00409
Vancouver
Weinmann C, Waibl F, Käser S, Casagrande F, Zhang JD, Dey F, et al. Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides. Molecular Pharmaceutics. 2026;23(10):4872-4883. doi:10.1021/acs.molpharmaceut.6c00409
BibTeX
@article{Weinmann2026,
author = {Weinmann, Christian and Waibl, Franz and Käser, Silvan and Casagrande, Fabio and Zhang, Jitao David and Dey, Fabian and Wagner, Björn and Schulze, Britta and Kroll, Carsten and Keemink, Janneke},
title = {Dynlog P A Novel High-Throughput LC−MS Assay Quantifying Dynamic Lipophilicity and Chameleonicity of bRo5 Macrocyclic Peptides},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {10},
pages = {4872--4883},
doi = {10.1021/acs.molpharmaceut.6c00409}
}
EUVIMED